Fogorvosi szemle, 1993 (86. évfolyam, 1-11. szám)

1993-04-01 / 4. szám

Mineral Res. 1: Suppi. 147. 1986. — 42. Hausmann, E., Raisz, L. О. dk Miller, W. А.: Endotoxiin simulation of bone resorption in tisseu culture. Science 168, 862. 1970. — 43. Health, J. K. és mts.: Mouse osteoblasts synthetize colagenase in response to bone resorbing agents. Biochem. Biophys. Acta 802, 151. 1984. — 44. Hefti, E. és mts.: Increase of whole body calcium and skeletal mass in normal and osteopetrotic adult rats treated with parathyroid hormone. Clin. Sei. 62, 389. 1981. — 45. Hock, J. M. és mts.: Autoradiographic study of the effect of 1,25 dihydroxyvitamin D:) on bone matrix synthesis in vitamin D repleted rats. Calcif. Tissue Int. 34, 347. 1982. — 46. Hock, J. M. és mts.: Human parathyroid hormone-(l —34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 122, 2899. 1988. — 47. Holló I.: Primaer hyperparathyreosis ritka vagy túlságosan ritkán diagnosztizált betegség. Orvosi Hetik 123, 1711. 1982. — 48. Holló, I. és mts.: Postmenopausal osteoporosis: the effect of parathormone and large doses vitamin D3 on serum calcium level in sex hormone deficient rats. Acta Med. Acad. Sei. Hung. 32, 225. 1975. — 49. Holló, I. és mts.: Effect of sex hormone deficiency on calcitonin-induced hypocalcaemia. Akt. Gerontol. 5, 609. 1971. — 50. Holló, I.: Hormonok és endokrin betegségek hatása a felnőttek csontszövetére. Orvosi Hetik 129, 1351. 1988. — 51. Holló, 1.: Anyagcsere-csontbetegségek a felnőttkorban. Medicina. 1986. — 52. Holtrop, M. E. de Raisz, L. G.: Comparison of the effects of 1,25 dihydroxycholecalciferol, prostaglandin E2 and osteoclast activating factor with parathyroid hormone on the ultrastructure of ostaoclasts in cultured long bones of fetal rats. Calcif. Tissue Int. 29, 201. 1979. -- 53. Holtrop, 3/. E. és mts.: The effect of parathyroid hormone, colchicine and calcitonin on the ultrastructure and activity of osteoclasts in organ culture. J. Cell. Biol. 60, 346. 1974. — 54. Howard, G. A. és mts.: Evidence for the coupoling of bone formation and bone resortion in vitro. Metab. Bone Dis. Rel. Res. 2. 131. 1980.

— 55. Ibbotson, K. J. és mts.: Identification and characterization of osteoclast like cells and their progenitors in cultures of feline marrow mononuclear cells. J. Cell. Biol. 99, 471. 1984.

— 56. Javorski, Z. F. G.: Coupling of bone formation to bone resorption: A broader view. Calci. Tissue Int. 36, 531. 1984. — 57. Johnston, C. C. dk Deiss, W. P.: An inhibitory effect of thyrocalcitonin on calcium release in vivo and on bone metabolism in vitro. Endocrinology 78, 1139. 1966. — 58. Katz, J. M. és mts.: Bone resorption and prostaglandin production by mouse calvaria in vitro: Response to exogenous prostaglandins and their precursor fatty acids. Prostaglandins 22, 537. 1981. — 59. Kleis, D. C. <fc Raisz, L. G.: Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 86, 1436. 1970. — 60. Kodicek, E.: The story of vitamin D: From vitamin to hormone. Lancet ii, 235. 1974. — 61. Kream, B. E. és mts.: A specific high-affinity binding macromolecule for 1.25-dihydroxyvitamin D;) in fetal bone. Science 197, 1086. 1977. — 62. Lorenzo, J. A. és mts.: DNA synthesis is not necessary for osteoclastic responses to parathyroid hormone in cultured fetal rat long bones. J. Clin. Invest. 72, 1924. 1983. — 63. Luben, R. A. és mts.: Biochemical caracterisation with parathormone and calcitonin of isolated bone cells: provisional identification of osteoclasts and osteoblasts. Endocrinology 99, 526. 1976. — 64. Lund, J. E. és mts.: The toxicology of PGE, and PGE.2. In: Wu. KK. & Rossi EC (eds) Prostaglandins in clinical medicine: cardiovascular and thrombotic disorders. Year Book Medical Publishers, pp: 93—103 1982.

— 65. MacDonald, B. R.: Parathyroid hormone, prostaglandins and bone resorption. Wld. Rev. Nutr. Diet. 47, 163. 1986. — 66. Majeska, R. J. <1- Rodan, G. A.: Alkaline phosphatase inhibition by parathyroid hormone and isoproterenol in clonal rat osteosarcoma cell line: possible mediation by cyclic AMP. Calcif Tissue Int. 34, 59. 1982. — 67. Manolages, S. C. és mts.: High specific binding of 1,25 dihydroxycholeclaciferol in bone cytosol. J. Endocrinol. 80, 35. 1979. — 68. Martin, T. J.: The mode of action of thyrocalcitonin. Lancet i, 900. 1966.

— 69. Martin, T. J.: Drug and hormone effects on calcium release from bone. Pharmac Ther 21, 209. 1983. — 70. McGguire, J. L. dk Marks, 8. C.: The effects of parathyroid hormone on bone cell structure and function. Clin. Orthop. and Rel. Res. 100, 392. 1974. — 71. Meisen,

F. dk Mosekilde, L.: Morphometric and dynamic studies of bone changes in hyperparathroidism. Acta Pathol. Microbiol. Scan. 85A, 141. 1977. — 72. Nicholson, G. C. és mts.: Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J. Clin. Invest. 78, 355. 1986. — 73. Omdhal, J. L. dk DeLuca, H. F.: Rachitogenetic activity of dietary stroncium. J. Biol. Chem. 2247, 5520. 1972. — 74. Parker, C. L. és mts.: Development of cyclic AMP response to parathyroid hormone and prostaglandin E2 in

117